Nirsevimab
Phase 3Active 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Respiratory Syncytial Virus Infections
Conditions
Respiratory Syncytial Virus Infections
Trial Timeline
Jul 27, 2023 → Aug 15, 2025
NCT ID
NCT06042049About Nirsevimab
Nirsevimab is a phase 3 stage product being developed by AstraZeneca for Respiratory Syncytial Virus Infections. The current trial status is active. This product is registered under clinical trial identifier NCT06042049. Target conditions include Respiratory Syncytial Virus Infections.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06042049 | Phase 3 | Active |
| NCT05437510 | Phase 3 | Completed |
| NCT04840849 | Phase 1 | Completed |
| NCT04484935 | Phase 2 | Completed |
Competing Products
20 competing products in Respiratory Syncytial Virus Infections